A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell … (NCT07654400) | Clinical Trial Compass
Not Yet RecruitingPhase 2
A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
China36 participantsStarted 2026-07
Plain-language summary
This Phase II study is a clinical study exploring the efficacy and safety of BL-M14D1 in combination with Atezolizumab in patients with extensive-stage small cell lung cancer.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Voluntarily sign the informed consent form and comply with the protocol requirements;
. No gender restriction;
. Age: ≥18 years;
. Expected survival time ≥3 months;
. Histopathologically and/or cytologically confirmed extensive-stage small cell lung cancer that is incurable or for which there is currently no standard treatment;
. Agree to provide archived tumor tissue specimens from the primary or metastatic lesion within 3 years, or fresh tissue samples;
. Must have at least one measurable lesion as defined by RECIST v1.1;
. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
Exclusion criteria
. Use of chemotherapy, biological therapy, immunotherapy, etc., within 4 weeks or 5 half-lives before the first dose;
. Previous treatment with ADC drugs using topoisomerase I inhibitors as toxins;
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial combines BL-M14D1 with atezolizumab for extensive-stage small cell lung cancer — can you explain what BL-M14D1 is and how adding it to atezolizumab might work differently from the standard treatments I could receive right now?
2Since this is a Phase 2 trial that hasn't started recruiting yet, what does that mean for how much safety and effectiveness data exists so far, and how should I weigh that against going with an established treatment option?
3The trial is measuring objective response rate and treatment-emergent adverse events as its main goals — what kinds of side effects have been seen with similar drug combinations, and are there any risks that would be especially important given my specific health situation?
4Because this study isn't recruiting yet, how long might I realistically be waiting before I could even be considered for enrollment, and is waiting a safe option given where my cancer is right now?
5Would starting standard first-line treatment now affect my eligibility for this trial later, or is it worth discussing whether to hold off and wait for this study to open?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.